(Q34740927)

4 August 2017

1 reference

title

Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease (English)

1 reference

4 August 2017

0 references

2

Bart De Strooper

1 reference

4 August 2017

Diana Ines Dominguez

1

1 reference

4 August 2017

publication date

1 July 2002

1 reference

Trends in Pharmacological Sciences

4 August 2017

published in

1 reference

4 August 2017

volume

23

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

324-330

1 reference

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

1 reference

7 January 2021

Alzheimer's disease and Abeta toxicity: from top to bottom

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Abeta-generating enzymes: recent advances in beta- and gamma-secretase research

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

BACE1 is the major beta-secretase for generation of Abeta peptides by neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Presenilins and the intramembrane proteolysis of proteins: facts and fiction.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Aph-2/Nicastrin: an essential component of gamma-secretase and regulator of Notch signaling and Presenilin localization

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Presenilin-dependent gamma-secretase activity modulates thymocyte development

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Gamma -secretase inhibitors repress thymocyte development

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Amyloid-lowering isocoumarins are not direct inhibitors of gamma-secretase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Statins and the risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

An inflammatory drug prospect

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Evidence for genetic linkage of Alzheimer's disease to chromosome 10q

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Metabolic regulation of brain Abeta by neprilysin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

The plasmin system is induced by and degrades amyloid-beta aggregates

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Rapid induction of Alzheimer A beta amyloid formation by zinc.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

Cholinesterase inhibitors for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902038-2

7 January 2021

10.1016/S0165-6147(02)02038-2

Identifiers

DOI

1 reference

4 August 2017

1 reference